Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)
Genzyme,
a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that it
has received a Company Award from EURORDIS, the largest European patient
organization in the field of rare diseases. The EURORDIS Company Award
recognizes the outstanding accomplishments of companies dedicated to
rare diseases. Genzyme was honored for pioneering the development and
delivery of therapies for rare diseases, its longstanding support of
patient organizations, including EURORDIS, as well as initiatives to
increase patient access to Genzyme treatments.
EURORDIS Award recipients are selected by the EURORDIS Board of
Directors, from over 100 nominations received from EURORDIS members
(rare disease patient advocacy groups from all Europe), volunteers and
staff, with the aim of promoting leadership and excellence for people
living with rare diseases. Genzyme’s Senior Vice President of Rare
Diseases in Europe, Hilde Furberg, accepted the award yesterday during
the EURORDIS Black Pearl Gala Dinner in Brussels as EURORDIS began its
activities to recognize International Rare Disease Day.
“Genzyme has been partnering with patient advocacy organizations
globally from our earliest days to be sure the community’s needs and
perspectives are always represented within our organization, and the
contributions of these organizations remain central to Genzyme and our
ability to bring therapies to patients,” said Genzyme’s Head of Rare
Diseases, Rogerio Vivaldi, MD. “As we approach Rare Disease Day, a day
made possible because of EURORDIS, Genzyme wants to thank all of the
patient organizations and communities who work daily to improve the
lives of patients living with rare diseases. Their pioneering spirit
will continue to inspire Genzyme.”
Yann Le Cam, Chief Executive Officer of EURORDIS, said, "We are honored
to acknowledge the commitment and achievements of this year’s recipients
of the EURORDIS Awards on the occasion of Rare Disease Day 2013. Each of
this year’s ten awardees contributes in their own unique way toward
fostering the goals of cooperation embodied in this year’s Rare Disease
Day slogan: ‘Rare Disorders without Borders.’ We are proud that the rare
disease community is becoming a model for multi-stakeholder partnership
and international collaboration as well as for solidarity and unity
throughout Europe.”
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative
therapies for patients affected by rare and debilitating diseases for
over 30 years. We accomplish our goals through world-class research and
with the compassion and commitment of our employees. With a focus on
rare diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve. That
goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around the
world, represents groundbreaking and life-saving advances in medicine.
As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at www.genzyme.com.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients’ needs. Sanofi
has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Genzyme® is a registered trademark. All
rights reserved
